Revvity (NYSE:RVTY) Hits New 1-Year High – Time to Buy?

Revvity Inc. (NYSE:RVTY) shares hit a new 52-week high on Thursday . The stock traded as high as $118.34 and last traded at $117.8960, with a volume of 46220 shares. The stock had previously closed at $117.88.

Analysts Set New Price Targets

RVTY has been the topic of a number of research analyst reports. Evercore reiterated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Sanford C. Bernstein initiated coverage on Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Finally, Barclays boosted their target price on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $108.36.

Revvity Price Performance

The company’s fifty day moving average is $108.95 and its two-hundred day moving average is $99.96. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The firm has a market cap of $13.05 billion, a price-to-earnings ratio of 55.75, a price-to-earnings-growth ratio of 2.11 and a beta of 1.07.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same period in the prior year, the firm earned $1.18 EPS. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts forecast that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

Institutional Investors Weigh In On Revvity

Hedge funds have recently modified their holdings of the stock. Ascentis Independent Advisors purchased a new position in Revvity in the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC purchased a new stake in shares of Revvity during the second quarter valued at approximately $32,000. MUFG Securities EMEA plc purchased a new stake in shares of Revvity during the second quarter valued at approximately $34,000. SJS Investment Consulting Inc. lifted its position in shares of Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new position in shares of Revvity during the second quarter worth $49,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.